Greta A Bushnell1, Til Stürmer2, Alice White2, Virginia Pate2, Sonja A Swanson3, Deborah Azrael4, Matthew Miller5. 1. Department of Epidemiology, University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, NC, USA. Electronic address: gbushnel@live.unc.edu. 2. Department of Epidemiology, University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, NC, USA. 3. Department of Epidemiology, Harvard University, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands. 4. Department of Health Policy and Management, Harvard University, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 5. Department of Health Science, Northeastern University, Bouvé College of Health Sciences, Boston, MA, USA.
Abstract
BACKGROUND: Many patients with major depressive disorder (MDD) who begin antidepressant treatment discontinue use before for six months, the recommended minimum treatment length. This study sought to identify predictors of six-month antidepressant persistence including predictors utilizing patients' electronic prescription records. METHODS: Commercially insured children (3-17 years) and adults (18-64 years) with MDD who initiated antidepressant treatment, 1/1/2003-2/28/2010, were assessed for six-month persistence (based on prescriptions' days supply, allowing a 30-day grace period). Antidepressant persistence prediction models were developed separately for children and adults. Two additional measures, days without medication between the first and second antidepressant fill (children and adults) and prior persistence on other medications (adults only), were added to the models, concordance (c) statistics were compared and risk reclassification evaluated. RESULTS: Among children (n=8837 children) and adults (n=47,495) with MDD, six-month antidepressant persistence was low and varied by age (37%, 18-24 years to 52%, 3-12 and 50-64 years). Independent baseline predictors of persistence were identified, with model c-statistics: children=0.582, adults=0.584. Patients with more days without medication between fills were less likely to be persistent (10-30 vs. 0 days, children: RR=0.72, adults: RR=0.74), as were adults not previously persistent to other medications (RR=0.73). LIMITATIONS: The definition of six-month persistence is dependent on correct days supply values and the grace period utilized; potential predictors were limited to measures available in claims data. CONCLUSIONS: Six-month antidepressant persistence was low and overall prediction of persistence was poor; however, days without medication between fills and prior persistence on other medications marginally improved the ability to predict antidepressant persistence.
BACKGROUND: Many patients with major depressive disorder (MDD) who begin antidepressant treatment discontinue use before for six months, the recommended minimum treatment length. This study sought to identify predictors of six-month antidepressant persistence including predictors utilizing patients' electronic prescription records. METHODS: Commercially insured children (3-17 years) and adults (18-64 years) with MDD who initiated antidepressant treatment, 1/1/2003-2/28/2010, were assessed for six-month persistence (based on prescriptions' days supply, allowing a 30-day grace period). Antidepressant persistence prediction models were developed separately for children and adults. Two additional measures, days without medication between the first and second antidepressant fill (children and adults) and prior persistence on other medications (adults only), were added to the models, concordance (c) statistics were compared and risk reclassification evaluated. RESULTS: Among children (n=8837 children) and adults (n=47,495) with MDD, six-month antidepressant persistence was low and varied by age (37%, 18-24 years to 52%, 3-12 and 50-64 years). Independent baseline predictors of persistence were identified, with model c-statistics: children=0.582, adults=0.584. Patients with more days without medication between fills were less likely to be persistent (10-30 vs. 0 days, children: RR=0.72, adults: RR=0.74), as were adults not previously persistent to other medications (RR=0.73). LIMITATIONS: The definition of six-month persistence is dependent on correct days supply values and the grace period utilized; potential predictors were limited to measures available in claims data. CONCLUSIONS: Six-month antidepressant persistence was low and overall prediction of persistence was poor; however, days without medication between fills and prior persistence on other medications marginally improved the ability to predict antidepressant persistence.
Authors: Elizabeth Lewis; Steven C Marcus; Mark Olfson; Benjamin G Druss; Harold Alan Pincus Journal: Psychiatr Serv Date: 2004-05 Impact factor: 3.084
Authors: Robert J Valuck; Anne M Libby; Heather D Orton; Elaine H Morrato; Richard Allen; Ross J Baldessarini Journal: Am J Psychiatry Date: 2007-08 Impact factor: 18.112
Authors: Maarten J G Leening; Moniek M Vedder; Jacqueline C M Witteman; Michael J Pencina; Ewout W Steyerberg Journal: Ann Intern Med Date: 2014-01-21 Impact factor: 25.391
Authors: Richard A Hansen; Stacie B Dusetzina; Rosalie C Dominik; Bradley N Gaynes Journal: Pharmacoepidemiol Drug Saf Date: 2010-01 Impact factor: 2.890
Authors: Jennifer L Hargrove; Virginia Pate; Carri H Casteel; Yvonne M Golightly; Laura R Loehr; Stephen W Marshall; Til Stürmer Journal: Am J Hypertens Date: 2017-10-01 Impact factor: 2.689
Authors: Greta A Bushnell; M Alan Brookhart; Bradley N Gaynes; Scott N Compton; Stacie B Dusetzina; Til Stürmer Journal: Med Care Date: 2018-06 Impact factor: 2.983
Authors: Greta A Bushnell; Scott N Compton; Stacie B Dusetzina; Bradley N Gaynes; M Alan Brookhart; John T Walkup; Moira A Rynn; Til Stürmer Journal: J Clin Psychiatry Date: 2018 Jan/Feb Impact factor: 4.384
Authors: Alessandro S De Nadai; Marc S Karver; Tanya K Murphy; Mark A Cavitt; Jeffrey L Alvaro; Michael Bengtson; Saundra Stock; Andrew C Rakhshani; Eric A Storch Journal: J Child Adolesc Psychopharmacol Date: 2016-04-29 Impact factor: 2.576
Authors: Talia R Lester; Yair Bannett; Rebecca M Gardner; Heidi M Feldman; Lynne C Huffman Journal: Front Pediatr Date: 2022-03-17 Impact factor: 3.418